Skip to main content
Top
Published in: Respiratory Research 1/2011

Open Access 01-12-2011 | Research

Airflow limitation or static hyperinflation: which is more closely related to dyspnea with activities of daily living in patients with COPD?

Authors: Koichi Nishimura, Maya Yasui, Takashi Nishimura, Toru Oga

Published in: Respiratory Research | Issue 1/2011

Login to get access

Abstract

Background

Dyspnea while performing the activities of daily living has been suggested to be a better measurement than peak dyspnea during exercise. Furthermore, the inspiratory capacity (IC) has been shown to be more closely related to exercise tolerance and dyspnea than the FEV1, because dynamic hyperinflation is the main cause of shortness of breath in patients with COPD. However, breathlessness during exercise is measured in most studies to evaluate this relationship.

Purpose

To evaluate the correlation between breathlessness during daily activities and airflow limitation or static hyperinflation in COPD.

Methods

We examined 167 consecutive outpatients with stable COPD. The Baseline Dyspnea Index (BDI) was used to evaluate dyspnea with activities of daily living. The relationship between the BDI score and the clinical measurements of pulmonary function was then investigated.

Results

The Spearman rank correlation coefficients (Rs) between the BDI score and the FEV1(L), FEV1(%pred) and FEV1/FVC were 0.60, 0.56 and 0.56, respectively. On the other hand, the BDI score also correlated with the IC, IC/predicted total lung capacity (TLC) and IC/TLC (Rs = 0.45, 0.46 and 0.47, respectively). Although all of the relationships studied were strongly correlated, the correlation coefficients were better between dyspnea and airflow limitation than between dyspnea and static hyperinflation. In stepwise multiple regression analyses, the BDI score was most significantly explained by the FEV1 (R2 = 26.2%) and the diffusion capacity for carbon monoxide (R2 = 14.4%) (Cumulative R2 = 40.6%). Static hyperinflation was not a significant factor for clinical dyspnea on the stepwise multiple regression analysis.

Conclusion

Both static hyperinflation and airflow limitation contributed greatly to dyspnea in COPD patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference O'Donnell DE, Laveneziana P: The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006, 3 (4): 219-232. 10.1080/15412550600977478.CrossRefPubMed O'Donnell DE, Laveneziana P: The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006, 3 (4): 219-232. 10.1080/15412550600977478.CrossRefPubMed
2.
go back to reference O'Donnell DE, Laveneziana P: Dyspnea and activity limitation in COPD: mechanical factors. COPD. 2007, 4 (3): 225-236. 10.1080/15412550701480455.CrossRefPubMed O'Donnell DE, Laveneziana P: Dyspnea and activity limitation in COPD: mechanical factors. COPD. 2007, 4 (3): 225-236. 10.1080/15412550701480455.CrossRefPubMed
3.
go back to reference O'Donnell DE, Webb KA: The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol. 2008, 105 (2): 753-755. 10.1152/japplphysiol.90336.2008b. discussion 755-757CrossRefPubMed O'Donnell DE, Webb KA: The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol. 2008, 105 (2): 753-755. 10.1152/japplphysiol.90336.2008b. discussion 755-757CrossRefPubMed
4.
go back to reference O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004, 23 (6): 832-840. 10.1183/09031936.04.00116004.CrossRefPubMed O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004, 23 (6): 832-840. 10.1183/09031936.04.00116004.CrossRefPubMed
5.
go back to reference O'Donnell DE, Lam M, Webb KA: Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 158 (5 Pt 1): 1557-1565.CrossRefPubMed O'Donnell DE, Lam M, Webb KA: Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 158 (5 Pt 1): 1557-1565.CrossRefPubMed
6.
go back to reference O'Donnell DE, Lam M, Webb KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999, 160 (2): 542-549.CrossRefPubMed O'Donnell DE, Lam M, Webb KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999, 160 (2): 542-549.CrossRefPubMed
7.
go back to reference O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K: Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006, 130 (3): 647-656. 10.1378/chest.130.3.647.CrossRefPubMed O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K: Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006, 130 (3): 647-656. 10.1378/chest.130.3.647.CrossRefPubMed
8.
go back to reference O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA: Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004, 24 (1): 86-94. 10.1183/09031936.04.00072703.CrossRefPubMed O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA: Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004, 24 (1): 86-94. 10.1183/09031936.04.00072703.CrossRefPubMed
9.
go back to reference Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR: Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005, 171 (6): 591-597.CrossRefPubMed Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR: Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005, 171 (6): 591-597.CrossRefPubMed
10.
go back to reference Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T: Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 158 (4): 1185-1189.CrossRefPubMed Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T: Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 158 (4): 1185-1189.CrossRefPubMed
11.
go back to reference Oga T, Nishimura K, Tsukino M, Hajiro T, Mishima M: Dyspnoea with activities of daily living versus peak dyspnoea during exercise in male patients with COPD. Respir Med. 2006, 100 (6): 965-971. 10.1016/j.rmed.2005.10.006.CrossRefPubMed Oga T, Nishimura K, Tsukino M, Hajiro T, Mishima M: Dyspnoea with activities of daily living versus peak dyspnoea during exercise in male patients with COPD. Respir Med. 2006, 100 (6): 965-971. 10.1016/j.rmed.2005.10.006.CrossRefPubMed
12.
go back to reference Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P: Standardisation of spirometry. Eur Respir J. 2005, 26 (2): 319-338. 10.1183/09031936.05.00034805.CrossRefPubMed Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P: Standardisation of spirometry. Eur Respir J. 2005, 26 (2): 319-338. 10.1183/09031936.05.00034805.CrossRefPubMed
13.
go back to reference Diseases JSoC: The predicted values of pulmonary function testing and artrial blood gas in Japanese [in Japanese]. Jpn J Thorac Dis. 2001, 39 (5): appendix- Diseases JSoC: The predicted values of pulmonary function testing and artrial blood gas in Japanese [in Japanese]. Jpn J Thorac Dis. 2001, 39 (5): appendix-
14.
go back to reference Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997, 350 (9088): 1349-1353. 10.1016/S0140-6736(97)06031-5.CrossRefPubMed Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997, 350 (9088): 1349-1353. 10.1016/S0140-6736(97)06031-5.CrossRefPubMed
15.
go back to reference Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984, 85 (6): 751-758. 10.1378/chest.85.6.751.CrossRefPubMed Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984, 85 (6): 751-758. 10.1378/chest.85.6.751.CrossRefPubMed
16.
go back to reference Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T: Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 157 (3 Pt 1): 785-790.CrossRefPubMed Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T: Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 157 (3 Pt 1): 785-790.CrossRefPubMed
17.
go back to reference Murariu C, Ghezzo H, Milic-Emili J, Gautier H: Exercise limitation in obstructive lung disease. Chest. 1998, 114 (4): 965-968. 10.1378/chest.114.4.965.CrossRefPubMed Murariu C, Ghezzo H, Milic-Emili J, Gautier H: Exercise limitation in obstructive lung disease. Chest. 1998, 114 (4): 965-968. 10.1378/chest.114.4.965.CrossRefPubMed
18.
go back to reference Calverley PM: Dynamic hyperinflation: is it worth measuring?. Proc Am Thorac Soc. 2006, 3 (3): 239-244. 10.1513/pats.200508-084SF.CrossRefPubMed Calverley PM: Dynamic hyperinflation: is it worth measuring?. Proc Am Thorac Soc. 2006, 3 (3): 239-244. 10.1513/pats.200508-084SF.CrossRefPubMed
19.
go back to reference Eakin EG, Kaplan RM, Ries AL: Measurement of dyspnoea in chronic obstructive pulmonary disease. Qual Life Res. 1993, 2 (3): 181-191. 10.1007/BF00435222.CrossRefPubMed Eakin EG, Kaplan RM, Ries AL: Measurement of dyspnoea in chronic obstructive pulmonary disease. Qual Life Res. 1993, 2 (3): 181-191. 10.1007/BF00435222.CrossRefPubMed
20.
go back to reference Chhabra SK, Gupta AK, Khuma MZ: Evaluation of three scales of dyspnea in chronic obstructive pulmonary disease. Ann Thorac Med. 2009, 4 (3): 128-132. 10.4103/1817-1737.53351.CrossRefPubMedPubMedCentral Chhabra SK, Gupta AK, Khuma MZ: Evaluation of three scales of dyspnea in chronic obstructive pulmonary disease. Ann Thorac Med. 2009, 4 (3): 128-132. 10.4103/1817-1737.53351.CrossRefPubMedPubMedCentral
21.
go back to reference Ozalevli S, Ucan ES: The comparison of different dyspnoea scales in patients with COPD. J Eval Clin Pract. 2006, 12 (5): 532-538. 10.1111/j.1365-2753.2006.00658.x.CrossRefPubMed Ozalevli S, Ucan ES: The comparison of different dyspnoea scales in patients with COPD. J Eval Clin Pract. 2006, 12 (5): 532-538. 10.1111/j.1365-2753.2006.00658.x.CrossRefPubMed
22.
go back to reference Wijkstra PJ, TenVergert EM, van der Mark TW, Postma DS, Van Altena R, Kraan J, Koeter GH: Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. Thorax. 1994, 49 (5): 468-472. 10.1136/thx.49.5.468.CrossRefPubMedPubMedCentral Wijkstra PJ, TenVergert EM, van der Mark TW, Postma DS, Van Altena R, Kraan J, Koeter GH: Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. Thorax. 1994, 49 (5): 468-472. 10.1136/thx.49.5.468.CrossRefPubMedPubMedCentral
23.
go back to reference Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A: Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002, 39 (2): 202-209. 10.1016/S0735-1097(01)01744-2.CrossRefPubMed Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A: Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002, 39 (2): 202-209. 10.1016/S0735-1097(01)01744-2.CrossRefPubMed
24.
go back to reference Pesola GR: The use of B-type natriuretic peptide (BNP) to distinguish heart failure from lung disease in patients presenting with dyspnea to the emergency department. Acad Emerg Med. 2003, 10 (3): 275-277. 10.1111/j.1553-2712.2003.tb02003.x.CrossRefPubMed Pesola GR: The use of B-type natriuretic peptide (BNP) to distinguish heart failure from lung disease in patients presenting with dyspnea to the emergency department. Acad Emerg Med. 2003, 10 (3): 275-277. 10.1111/j.1553-2712.2003.tb02003.x.CrossRefPubMed
Metadata
Title
Airflow limitation or static hyperinflation: which is more closely related to dyspnea with activities of daily living in patients with COPD?
Authors
Koichi Nishimura
Maya Yasui
Takashi Nishimura
Toru Oga
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2011
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-12-135

Other articles of this Issue 1/2011

Respiratory Research 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine